Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 125

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 125
---
                                       | ​ | ​ | ​                                           | ​                      | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |   |   |   |   |   |   |   |

130 | investor.pacira.com

TABLE OF CONTENTS

| ​ | ​ | APPENDIX A | ​ |

| ​ | ​                           | ​ | ​ | ​                                   | ​ | ​ | ​            | ​ | ​ | ​                 | ​ | ​ | ​                     | ​ | ​ | ​                         | ​ | ​ | ​                                           | ​ | ​ | ​                     | ​ | ​ |            | ​ | ​ | ​          | ​ |
| ​ | 2025PROXY STATEMENT SUMMARY | ​ | ​ | CORPORATEGOVERNANCEAND BOARDMATTERS | ​ | ​ | AUDITMATTERS | ​ | ​ | EXECUTIVEOFFICERS | ​ | ​ | EXECUTIVECOMPENSATION | ​ | ​ | STOCKOWNERSHIPINFORMATION | ​ | ​ | INFORMATIONABOUT THEANNUALMEETING ANDVOTING | ​ | ​ | ADDITIONALINFORMATION | ​ | ​ | APPENDIX A | ​ | ​ | APPENDIX B | ​ |

TABLE OF CONTENTS Appendix A

| ​ | ​ | Appendix A | ​ |

Reconciliation of U.S. GAAP Net INCOME (LOSS) to Adjusted EBITDA This document contains a financial measure that does not comply with U.S. generally accepted accounting principles (GAAP), which we refer to as adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), because this non-GAAP financial measure excludes the impact of items that management believes affect comparability or underlying business trends. This measure supplements the company’s financial results prepared in accordance with GAAP. Pacira management uses this measure to better analyze its financial results and to help make managerial decisions. In management’s opinion, this non-GAAP measure is useful to investors and other users of the Company’s financial statements by providing greater transparency into the ongoing operating performance of Pacira and its future outlook. Such a measure should not be deemed to be an alternative to GAAP requirements or a measure of liquidity for Pacira. The non-GAAP measure presented here is also unlikely to be comparable with non-GAAP disclosures released by other companies. See the table below for a reconciliation of GAAP net loss to adjusted EBITDA.

| RECONCILIATION OF U.S. GAAP NET IN